$28.94 Million in Sales Expected for LeMaitre Vascular Inc (NASDAQ:LMAT) This Quarter

Analysts forecast that LeMaitre Vascular Inc (NASDAQ:LMAT) will report sales of $28.94 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for LeMaitre Vascular’s earnings, with estimates ranging from $28.70 million to $29.11 million. LeMaitre Vascular posted sales of $27.02 million during the same quarter last year, which would indicate a positive year over year growth rate of 7.1%. The firm is scheduled to report its next earnings report on Thursday, July 25th.

On average, analysts expect that LeMaitre Vascular will report full year sales of $114.10 million for the current fiscal year, with estimates ranging from $113.90 million to $114.30 million. For the next fiscal year, analysts expect that the firm will report sales of $121.69 million, with estimates ranging from $120.10 million to $122.64 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, May 1st. The medical instruments supplier reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.02). The company had revenue of $28.48 million for the quarter, compared to analysts’ expectations of $27.94 million. LeMaitre Vascular had a return on equity of 16.76% and a net margin of 20.92%. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.19 EPS.

Several analysts have recently weighed in on LMAT shares. BidaskClub upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research report on Saturday, May 4th. Barrington Research restated a “buy” rating and set a $32.00 price objective on shares of LeMaitre Vascular in a research report on Thursday, May 2nd. Finally, ValuEngine upgraded shares of LeMaitre Vascular from a “sell” rating to a “hold” rating in a research report on Friday, April 26th. Six analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. LeMaitre Vascular has an average rating of “Hold” and an average target price of $31.00.

Shares of NASDAQ:LMAT opened at $27.56 on Wednesday. The stock has a market cap of $544.70 million, a P/E ratio of 32.81, a PEG ratio of 2.78 and a beta of 1.17. LeMaitre Vascular has a twelve month low of $21.79 and a twelve month high of $38.99. The business’s 50 day moving average is $26.92.

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 6th. Investors of record on Wednesday, May 22nd were given a $0.085 dividend. The ex-dividend date was Tuesday, May 21st. This represents a $0.34 annualized dividend and a yield of 1.23%. LeMaitre Vascular’s dividend payout ratio (DPR) is 40.48%.

Hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can boosted its holdings in shares of LeMaitre Vascular by 99.1% during the fourth quarter. Bank of Montreal Can now owns 1,113 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 554 shares during the period. Rhumbline Advisers raised its position in shares of LeMaitre Vascular by 10.7% in the fourth quarter. Rhumbline Advisers now owns 86,336 shares of the medical instruments supplier’s stock valued at $2,041,000 after buying an additional 8,331 shares during the last quarter. Comerica Bank raised its position in shares of LeMaitre Vascular by 29.5% in the fourth quarter. Comerica Bank now owns 54,794 shares of the medical instruments supplier’s stock valued at $1,289,000 after buying an additional 12,495 shares during the last quarter. Oregon Public Employees Retirement Fund acquired a new stake in shares of LeMaitre Vascular in the fourth quarter valued at about $143,000. Finally, BlackRock Inc. raised its position in shares of LeMaitre Vascular by 2.2% in the fourth quarter. BlackRock Inc. now owns 2,601,309 shares of the medical instruments supplier’s stock valued at $61,496,000 after buying an additional 56,161 shares during the last quarter. Hedge funds and other institutional investors own 77.10% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Featured Article: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.